Shaanxi Dongke Pharmaceutical Co., Ltd. (hereinafter referred to as "Dongke Pharmaceutical") is a national high-tech enterprise integrating R&D, production and sales. The predecessor of Dongke Pharmaceutical was Yangling Dongke Madison Pharmaceutical Co., Ltd., which was established in Xian in 1993 and built a factory in Yangling in 1998. It was one of the first batch of key enterprises entering the zone in Yangling. In December 2014, Dongke Pharmaceutical entered into equity cooperation with Jichuan Pharmaceutical Group and became a wholly-owned subsidiary of Jichuan Pharmaceutical Group, with total assets of 1 billion yuan and more than 400 employees.
Jichuan Pharmaceutical Group is located in Taizhou City, Jiangsu Province. It is a national high-tech enterprise group integrating research and development, manufacturing, and commercial distribution of western medicine, traditional Chinese medicine cosmetics, and traditional Chinese medicine health products. It is a backbone enterprise in the national torch plan pharmaceutical industry and a national pharmaceutical company. Top 100 industrial enterprises, A-share listed company on the Shanghai Stock Exchange, stock code 600566.
The company has 42 national drug standards, 11 national exclusive products, 5 national exclusive formulations, 16 national medical insurance products, 6 national basic medicine products, and 24 invention patents. There are seven dosage forms of capsules, granules, tablets, rubber ointments, powders, patches, and ointments, covering the five core areas of respiratory, pediatrics, gynecology, digestion, and orthopedics.
In order to further expand production capacity, the company newly acquired 300 acres of land to build "Dongke Pharmaceutical Yangling Pharmaceutical Production Base" at No. 3 Zimao Street, Yangling Demonstration Zone. The total investment of the project is 1.5 billion yuan, and the total construction area is 290,000 square meters. The project is divided into two phases. Construction. The first phase of the project has an investment of 650 million yuan, a construction area of 130,000 square meters, and a designed production capacity of 1.5 billion yuan. It has been put into operation at present. Standing on the land of Yangling, it has become a new business card for biomedical enterprises in Yangling Demonstration Zone.
Since its establishment, Dongke Pharmaceutical has been recognized as a “National High-tech Enterprise, Shaanxi Enterprise Technology Center, Shaanxi Province Technological Innovation Demonstration Enterprise, Shaanxi Province Industrial Product Quality Control and Technology Evaluation Laboratory, and “Shaanxi Province Industrial Brand Cultivation Demonstration Enterprise ”, “Shaanxi Province Pharmaceutical Industry Advanced Group in Fighting New Coronary Epidemic”, the granulating team of solid preparation workshop was awarded “National Worker Pioneer”, and the company was awarded “Shaanxi Province Outstanding Private Enterprise, Shaanxi Province Quality Credit A Grade Enterprise, Shaanxi Province Advanced Safety Production "Unit" and other titles have been awarded "Yangling Economic Development Outstanding Contribution Award" for consecutive years; "Dongke" and "Yaowangshan" trademarks have been rated as well-known trademarks in Shaanxi Province, and the companys reputation and influence in the industry are increasing.
Dongke Pharmaceutical Centered on the group company’s strategic plan of "three industries to advance together", continued to deepen its cost-leading advantage, cultivated traditional Chinese medicine, expanded chemical medicine, cultivated a platform for special external preparations, built an efficient variety incubation base, promoted high-quality sustainable development of the company, and strived to be the first in the west. The first phalanx of the pharmaceutical industry is determined to become a national pharmaceutical enterprise trusted by the public.